Cost and cost-effectiveness of four different SARS-CoV-2 active surveillance strategies: evidence from a randomised control trial in Germany

Hoa Thi Nguyen (), Claudia M. Denkinger, Stephan Brenner, Lisa Koeppel, Lucia Brugnara, Robin Burk, Michael Knop, Till Bärnighausen, Andreas Deckert and Manuela De Allegri
Additional contact information
Hoa Thi Nguyen: Heidelberg Institute of Global Health, University Hospital and Medical Faculty, Heidelberg University
Claudia M. Denkinger: Heidelberg University Hospital
Stephan Brenner: Heidelberg Institute of Global Health, University Hospital and Medical Faculty, Heidelberg University
Lisa Koeppel: Heidelberg University Hospital
Lucia Brugnara: Heidelberg Institute of Global Health, University Hospital and Medical Faculty, Heidelberg University
Robin Burk: Heidelberg University
Michael Knop: Heidelberg University
Till Bärnighausen: Heidelberg Institute of Global Health, University Hospital and Medical Faculty, Heidelberg University
Andreas Deckert: Heidelberg Institute of Global Health, University Hospital and Medical Faculty, Heidelberg University
Manuela De Allegri: Heidelberg Institute of Global Health, University Hospital and Medical Faculty, Heidelberg University

The European Journal of Health Economics, 2023, vol. 24, issue 9, No 10, 1545-1559

Abstract: Abstract Introduction The COVID-19 pandemic has entered its third year and continues to affect most countries worldwide. Active surveillance, i.e. testing individuals irrespective of symptoms, presents a promising strategy to accurately measure the prevalence of SARS-CoV-2. We aimed to identify the most cost-effective active surveillance strategy for COVID-19 among the four strategies tested in a randomised control trial between 18th November 2020 and 23rd December 2020 in Germany. The four strategies included: (A1) direct testing of individuals; (A2) direct testing of households; (B1) testing conditioned on upstream COVID-19 symptom pre-screening of individuals; and (B2) testing conditioned on upstream COVID-19 symptom pre-screening of households. Methods We adopted a health system perspective and followed an activity-based approach to costing. Resource consumption data were collected prospectively from a digital individual database, daily time records, key informant interviews and direct observations. Our cost-effectiveness analysis compared each strategy with the status quo and calculated the average cost-effective ratios (ACERs) for one primary outcome (sample tested) and three secondary outcomes (responder recruited, case detected and asymptomatic case detected). Results Our results showed that A2, with cost per sample tested at 52,89 EURO, had the lowest ACER for the primary outcome, closely followed by A1 (63,33 EURO). This estimate was much higher for both B1 (243,84 EURO) and B2 (181,06 EURO). Conclusion A2 (direct testing at household level) proved to be the most cost-effective of the four evaluated strategies and should be considered as an option to strengthen the routine surveillance system in Germany and similar settings.

Keywords: COVID-19; Surveillance; Cost; Cost-effectiveness; Germany (search for similar items in EconPapers)
JEL-codes: I18 (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-022-01561-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:24:y:2023:i:9:d:10.1007_s10198-022-01561-8

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-022-01561-8

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().